Effect of Verapamil Tablets on the Pharmacokinetic of HRS-1893 Tablets in Healthy Subjects

Shandong Suncadia Medicine Co., Ltd.14 enrolled

Overview

The purpose of this phase Ⅰ study is to evaluate the effect of oral verapamil tablets on the pharmacokinetics of HRS-1893 in healthy subjects.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Obstructive Hypertrophic Cardiomyopathy

Interventions

HRS-1893 tabletDRUG

HRS-1893 tablet single dose

Verapamil tabletDRUG

Verapamil tablet 80 mg tid

Eligibility

Sex: ALLMin age: 18 YearsMax age: 55 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: 1. Understand the study procedures and methods, voluntarily participate in the study, comply with study requirements, and sign the written informed consent form (ICF). 2. Male or female aged 18-55（adult healthy volunteers). 3. Body mass index (BMI) between 19 and 28 kg/m2. 4. Normal Electrocardiogram (ECG). Exclusion Criteria: 1. History of persistent tachyarrhythmia and syncope. 2. A history of stomach or bowel surgery or excision. 3. Positive results of hepatitis B surface antigen, hepatitis C antibody, syphilis antibody and human immunodeficiency virus antibody. 4. Those who have participated in any clinical trials and have taken study drugs within 3 months before the first administration.

Locations (1)

Beijing Anzhen Hospital

Beijing, Beijing Municipality, China